ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
22.05 USD   +1.61%
05/20SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/20SECTOR UPDATE : Health Care
MT
05/20Anika Therapeutics Says FDA Approves X-Twist System for Soft Tissue Repair
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12/10/2021 | 05:00pm EDT

BEDFORD, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on December 1, 2021, Anika granted non-statutory stock options covering an aggregate of 1,069 shares of common stock (the “Options”) and restricted stock units (the “RSUs”) covering an aggregate of 468 shares of common stock to 1 newly hired non-executive employee. Each grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

The Options are exercisable, subject to vesting, at a per share exercise price of $38.53, which equals the closing price of a share of Anika’s common stock on the Nasdaq Global Select Market on the grant date. Of the shares covered by each of the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.

The RSUs will vest in three equal installments, with one-third of the shares covered by each of the RSUs vesting on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.

Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and the Options and RSUs are otherwise subject to the terms and conditions of the respective equity award agreements approved by Anika. The Options and RSUs were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, which was not subject to stockholder approval.

About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with clinicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. Anika is headquartered in Massachusetts with operations in the United States and Europe. For more information about Anika, please visit www.anika.com.

ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.

For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Executive Director, Investor Relations and Corporate Communications
investorrelations@anika.com


Primary Logo

Source: Anika Therapeutics Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about ANIKA THERAPEUTICS, INC.
05/20SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/20SECTOR UPDATE : Health Care
MT
05/20Anika Therapeutics Says FDA Approves X-Twist System for Soft Tissue Repair
MT
05/20Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Ex..
GL
05/20Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding..
CI
05/20Anika Therapeutics Gets FDA OK for X-Twist Knotless Fixation System
DJ
05/13Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
05/09Anika to Participate in the UBS Global Healthcare Conference 2022
AQ
05/06Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 2, 20..
CI
05/06ANIKA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
More news
Analyst Recommendations on ANIKA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 154 M - -
Net income 2022 -11,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -29,1x
Yield 2022 -
Capitalization 321 M 321 M -
Capi. / Sales 2022 2,08x
Capi. / Sales 2023 1,88x
Nbr of Employees 297
Free-Float 98,2%
Chart ANIKA THERAPEUTICS, INC.
Duration : Period :
Anika Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANIKA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 22,05 $
Average target price 37,50 $
Spread / Average Target 70,1%
EPS Revisions
Managers and Directors
Cheryl Renee Blanchard President, Chief Executive Officer & Director
Michael L. Levitz Chief Financial Officer, Treasurer & EVP
Jeffery S. Thompson Chairman
Mira Leiwant VP-Quality, Regulatory & Clinical Affairs
Steven W. Ek Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ANIKA THERAPEUTICS, INC.-38.46%321
CSL LIMITED-7.46%92 708
SAMSUNG BIOLOGICS CO.,LTD.-7.64%47 463
BIOGEN INC.-14.05%30 198
WUXI BIOLOGICS (CAYMAN) INC.-41.33%29 183
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-32.02%20 229